Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ximing Tang

Showing results (21-30 of 86) with videos related to

Pageof 9
Sort By:
Neoplasia (New York, N.Y.)|May 31, 2016
PIAS1-FAK Interaction Promotes the Survival and Progression of Non-Small Cell Lung CancerJerfiz D Constanzo, Ke-Jing Tang, Smita Rindhe, et al.
Neoplasia (New York, N.Y.)|July 3, 2019
Corrigendum to "PIAS1-FAK Interaction Promotes the Survival and Progression of Non-Small Cell Lung Cancer" [<i>Neoplasia</i> 18 (2016) 282-293]Jerfiz D Constanzo, Ke-Jing Tang, Smita Rindhe, et al.
Human Pathology|March 18, 2015
An update on clinicopathological, immunohistochemical, and molecular profiles of colloid carcinoma of the lungMaryam J Zenali, Annikka Weissferdt, Luisa M Solis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 10, 2003
Lack of interleukin-10 expression could predict poor outcome in patients with stage I non-small cell lung cancerJean-Charles Soria, Chulso Moon, Bonnie L Kemp, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2007
KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancerErminia Massarelli, Marileila Varella-Garcia, Ximing Tang, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|March 10, 2009
Epithelial-to-mesenchymal transition in the development and progression of adenocarcinoma and squamous cell carcinoma of the lungLudmila Prudkin, Diane D Liu, Natalie C Ozburn, et al.
Frontiers in Immunology|September 22, 2023
Allogeneic cord blood regulatory T cells decrease dsDNA antibody and improve albuminuria in systemic lupus erythematosusMi-Ae Lyu, Ximing Tang, Joseph D Khoury, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2009
HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumorsMenghong Sun, Carmen Behrens, Lei Feng, et al.
International Journal of Radiation Oncology, Biology, Physics|May 14, 2015
Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung CancerRitsuko Komaki, Pamela K Allen, Xiong Wei, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 16, 2004
Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markersCharles Lu, Jean-Charles Soria, Ximing Tang, et al.
Pageof 9

Showing results (21-30 of 86) with videos related to

Sort By:
Pageof 9
Neoplasia (New York, N.Y.)|May 31, 2016
PIAS1-FAK Interaction Promotes the Survival and Progression of Non-Small Cell Lung CancerJerfiz D Constanzo, Ke-Jing Tang, Smita Rindhe, et al.
Neoplasia (New York, N.Y.)|July 3, 2019
Corrigendum to "PIAS1-FAK Interaction Promotes the Survival and Progression of Non-Small Cell Lung Cancer" [<i>Neoplasia</i> 18 (2016) 282-293]Jerfiz D Constanzo, Ke-Jing Tang, Smita Rindhe, et al.
Human Pathology|March 18, 2015
An update on clinicopathological, immunohistochemical, and molecular profiles of colloid carcinoma of the lungMaryam J Zenali, Annikka Weissferdt, Luisa M Solis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 10, 2003
Lack of interleukin-10 expression could predict poor outcome in patients with stage I non-small cell lung cancerJean-Charles Soria, Chulso Moon, Bonnie L Kemp, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2007
KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancerErminia Massarelli, Marileila Varella-Garcia, Ximing Tang, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|March 10, 2009
Epithelial-to-mesenchymal transition in the development and progression of adenocarcinoma and squamous cell carcinoma of the lungLudmila Prudkin, Diane D Liu, Natalie C Ozburn, et al.
Frontiers in Immunology|September 22, 2023
Allogeneic cord blood regulatory T cells decrease dsDNA antibody and improve albuminuria in systemic lupus erythematosusMi-Ae Lyu, Ximing Tang, Joseph D Khoury, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2009
HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumorsMenghong Sun, Carmen Behrens, Lei Feng, et al.
International Journal of Radiation Oncology, Biology, Physics|May 14, 2015
Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung CancerRitsuko Komaki, Pamela K Allen, Xiong Wei, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 16, 2004
Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markersCharles Lu, Jean-Charles Soria, Ximing Tang, et al.
Pageof 9